Celularity Announces Multi-Year Research Collaboration Services Agreement With Regeneron
August 29 2023 - 9:00AM
Celularity Inc. (Nasdaq: CELU) (Celularity), a biotechnology
company developing allogeneic cell therapies and biomaterial
products, announced today a multi-year Research Collaboration
Services Agreement with Regeneron Pharmaceuticals, Inc. (Regeneron)
to support the research of Regeneron’s allogeneic cell therapy
candidates.
The agreement’s initial focus is the research on a targeted
allogeneic gamma delta chimeric antigen receptor (CAR) T-cell
therapy owned by Regeneron designed to enhance proliferation and
potency against solid tumors. The research will take place at
Celularity’s state-of-the-art facility located in Florham Park,
N.J. Financial terms were not disclosed.
“The agreement with Regeneron announced today is an important
milestone for Celularity that recognizes our expertise in the
research of cellular therapies, including the engineering of CAR-T
cells. We believe that this relationship paves the way for future
industry collaborations leveraging our world class cell therapy
facilities and capabilities,” said Robert J. Hariri, M.D., Ph.D.,
Celularity’s CEO, Chairman and Founder. “We have long admired the
exceptional scientific legacy at Regeneron and welcome the
opportunity to collaborate with a world leader in innovative
medicines.”
About Celularity
Celularity Inc. (Nasdaq: CELU) headquartered in Florham Park,
N.J., is a biotechnology company leading the next evolution in
cellular and regenerative medicine by developing allogeneic
cryopreserved off-the-shelf placental-derived cell therapies,
including therapeutic programs using mesenchymal-like adherent
stromal cells (MLASCs), T-cells engineered with CAR (CAR T-cells),
and genetically modified and unmodified natural killer (NK) cells.
These therapeutic programs target indications in autoimmune,
infectious and degenerative diseases, and cancer. In addition,
Celularity develops, manufactures and commercializes innovative
biomaterial products also derived from the postpartum placenta.
Celularity believes that by harnessing the placenta’s unique
biology and ready availability, it can develop therapeutic
solutions that address significant unmet global needs for
effective, accessible, and affordable therapies.
To learn more, visit www.celularity.com.
Celularity’s Forward-Looking Statements
This press release includes “forward-looking statements” within
the meaning of The Private Securities Litigation Reform Act of
1995, as well as within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. All statements other
than statements of historical facts are “forward-looking
statements,” including those relating to future events. In some
cases, you can identify forward-looking statements by terminology
such as “anticipate,” “believe,” “can,” “contemplate,” “continue,”
“could,” “estimate,” “expect,” “forecast,” “intends,” “may,”
“might,” “outlook,” “plan,” “possible,” “potential,” “predict,”
“project,” “seek,” “should,” “strive,” “target,” “will,” “would”
and the negative of terms like these or other comparable
terminology, and other words or terms of similar meaning. The
forward-looking statements in this press release include statements
regarding the research collaboration services agreement with
Regeneron and the anticipated benefits of such collaboration, among
others. Many factors could cause actual results to differ
materially from those described in these forward-looking
statements, including but not limited to the risk that the research
collaboration with Regeneron is unsuccessful; the inherent risks in
biotechnological development; the risks associated with
Celularity’s current liquidity; developments relating to the
biotechnology industry, along with those risk factors set forth
under the caption “Risk Factors” in Celularity’s annual report on
Form 10-K filed with the Securities and Exchange Commission (SEC)
on March 31, 2023, and other filings with the SEC. These risks and
uncertainties may be amplified by current economic situations,
including inflation, supply chain issues and overall economic
uncertainty. If any of these risks materialize or underlying
assumptions prove incorrect, actual results could differ materially
from the results implied by these forward-looking statements. There
may be additional risks that Celularity does not presently know, or
that Celularity currently believes are immaterial, that could also
cause actual results to differ from those contained in the
forward-looking statements. In addition, these forward-looking
statements reflect Celularity’s current expectations, plans, or
forecasts of future events and views as of the date of this
communication. Subsequent events and developments could cause
assessments to change. Accordingly, forward-looking statements
should not be relied upon as representing Celularity’s views as of
any subsequent date, and Celularity undertakes no obligation to
update forward-looking statements to reflect events or
circumstances after the date hereof, whether as a result of new
information, future events or otherwise, except as may be required
under applicable securities laws.
Celularity Investor Contact:Carlos Ramirez,
Senior Vice PresidentCelularity
Inc.Carlos.ramirez@celularity.com
Celularity Media Contact:Factory
PRcelularity@factorypr.com
Celularity (NASDAQ:CELU)
Historical Stock Chart
From Apr 2024 to May 2024
Celularity (NASDAQ:CELU)
Historical Stock Chart
From May 2023 to May 2024